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Abstract
The aim of this chapter is to describe the main issues of bone tissue engineering. Bone
transplants are widely used in orthopedic, plastic and reconstructive surgery. Current
technologies like autologous and allogenic transplantation have several disadvantages
making them relatively unsatisfactory, like donor site morbidity, chronic pain, and
immunogenicity  and  risk  hazard  from  infectious  disease.  Therefore,  regenerative
orthopedics seeks to establish a successful protocol for the healing of severe bone damage
using engineered bone grafts. The optimization of protocols for bone graft production
using autologous mesenchymal stem cells loaded on appropriate scaffolds, exposed to
osteogenic inducers and mechanical force in bioreactor, should be able to solve the current
limitations in managing bone injuries. We discuss mesenchymal stem cells as the most
suitable cell type for bone tissue engineering. They can be isolated from a variety of
mesenchymal tissues and can differentiate into osteoblasts when given appropriate
mechanical support and osteoinductive signal. Mechanical support can be provided by
different cell scaffolds based on natural or synthetic biomaterials, as well as combined
composite  materials.  Three-dimensional  support  is  enabled  by  bioreactor  systems
providing several advantages as mechanical loading, homogeneous distribution of cells
and adequate nutrients/waste exchange. We also discuss the variety of osteoinductive
signals that can be applied in bone tissue engineering. The near future of bone healing
and regeneration is closely related to advances in tissue engineering. The optimization of
protocols of bone graft production using autologous mesenchymal stem cells loaded on
appropriate scaffolds, exposed to osteogenic inducers and mechanical force in bioreac‐
tor, should be able to solve the current limitations in managing bone injuries.
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1. Introduction
Tissue engineering is a multidisciplinary field that applies basic concepts and techniques of life
science and engineering. It is generally understood as a process of taking human or animal
tissues, isolating cells from the tissues, culturing the isolated cells in a supporting material, i.e.,
scaffold to fabricate cell-scaffold complex, and transplanting the fabricated cell-scaffold complex
into human or animal subject. It is applied to fabricate almost every human organ including
artificial skin, artificial bone, artificial cartilage, artificial cornea, artificial blood vessels and
artificial muscles.
Bone is one of the few organs/tissues capable of spontaneous regeneration rather than simple
repair. In other words, after disruption of its structure (fracture), its unique microanatomy and
biological properties enable complete structural restoration without the creation of fibrotic scar
tissue. However, in certain clinical situations where extensive injury, disease or malformation
cause such large defects, it is necessary to resort to bone reconstruction, restoration and/or
regeneration by a surgical procedure that replaces missing bone, i.e., by bone grafting. A bone
graft is an implanted material that promotes bone healing alone or in combination with other
material(s), through osteogenesis, osteoinduction and osteoconduction, in combination or
alone [1].
The selection of an ideal bone graft relies on several factors such as tissue viability, defect size,
graft size, shape and volume, biomechanical characteristics, graft handling, cost, ethical issues,
biological characteristics and associated complications. The materials used in bone grafting
can be divided into several major categories, including autografts, allografts, and xenografts.
Synthetic and biologically based, tissue-engineered biomaterials and combinations of these
substitutes are other options. Altogether, tissue-engineered bone graft requires the optimal
selection of cells that are seeded on biomaterial-based scaffolds and exposed to specific
biochemical and physical signals known to induce osteogenesis. The development of the
successful bone tissue-engineering protocols depends very much on our understanding of
bone structure, physiology and development.
Bone is a dynamic biological tissue consisting of metabolically active cells. The cell component
of bone consists of the precursor cells (progenitors), osteoblasts, osteoclasts, osteocytes and
bone marrow hematopoietic elements. Osteoblasts are metabolically active mature bone-
forming cells. They secrete osteoid, non-mineralized organic corpuscle that in turn undergoes
mineralization process. Osteocytes are mature osteoblasts trapped within the bone matrix.
Every osteocyte extends network of cytoplasmic tubules to the blood vessels and other cells.
These cells are involved in the control of extracellular calcium. Osteoclasts are large multi‐
nucleated cells that degrade bone. Beside cells, bone is also composed of organic and inorganic
elements. Approximately 20% of the weight of bone is water until the weight of dry inorganic
bone makes calcium phosphate (65–70%) and the organic matrix of fibrous proteins and
collagen (30–35%). Bone formation models in vitro are based on the fact that cell differentiation
and function can be modelled according to factors that are important for embryonic develop‐
ment. Stem cells represent the building blocks of our bodies, functioning as the natural units
of embryonic generation during development and adult regeneration following tissue
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damage. Stem cells are undifferentiated cells that can, under certain influence, differentiate
into specialized cells and tissues. During development, the potency of stem cells decreases
from totipotent stem cells (morula stage), capable of differentiating into all embryonic and
extra embryonic tissues, to pluripotent stem cells (PSCs) (blastocyst stage), forming all
embryonic tissues, and to multi- or unipotent adult stem cells (ASCs), forming tissues within
their germ layer or tissue compartment [2]. Here, we discuss clinically relevant multipotent
ASCs found in various adult tissues. Adult stem cells, also called somatic stem cells, in adult
organism act as repair system for the body, replenishing adult tissues, prompt tissue homeo‐
stasis throughout life and ensure tissue regeneration following damage and they have great
potential in regenerative medicine. Mesenchymal stem cells replenish connective tissues
including bone. Therefore, they are the first choice among ASCs for regeneration of bone tissue.
Osteogenic differentiation in vitro is induced by ascorbic acid, b-glycerophosphate and
dexamethasone. Ascorbic acid is essential for the development of osteoblasts, serves as a
cofactor in the synthesis of collagen and stimulates the production of extracellular matrix,
proliferation and differentiation of cells. b-Glycerophosphate serves as a source of phosphate
for the formation of calcium phosphate in vitro. It is also responsible for the formation of three-
dimensional bone nodules between cells as proof of realized osteoblast phenotype. Dexame‐
thasone (DEX) is composed by a synthetic glucocorticoid, which regulates the expression of
osteoblast genes, enhances differentiation in vitro, alkaline phosphatase activity and mineral‐
ization of bone. Understanding of osteoblast differentiation provided us the information on
key pathways’ components and enabled us the induction of differentiation using different
recombinant proteins like BMP-2, -6 to -9. Also, mechanical stimulation promotes osteoblast
differentiation and induces mineralization of extracellular matrix. Mechanical stimulation can
be achieved using steady and dynamic fluid flow in bioreactors. For this purpose, different
dynamic culture systems have been developed. These systems improve nutrient delivery to
the cells and generate shear stress that promotes cell differentiation into osteoblastic pheno‐
type. Bioreactors for bone engineering applications are broadly classified in few main catego‐
ries, including rotating wall vessels, spinner flasks, perfusion bioreactors and compression
systems. In addition to these, combinations of different bioreactors types have been explored
in order to better mimic the bone physiological environment in vitro, such as for example
compression bioreactors with added perfusion [3]. The process of bone tissue engineering in
three-dimensional dynamic bioreactor system is a recapitulation of bone healing process in
vivo in which progenitor cells, due to signals in the microenvironment, are stimulated to
differentiate into osteoblasts [4].
2. Cells in bone engineering
2.1. MSCs as the best choice
The important step in bone engineering is the choice of human cell sources that can efficiently
produce bone grafts when attached to proper mechanical support with the addition of
osteogenic supplements. Cell types that can be potentially used in bone engineering are
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primary osteogenic cells isolated from adult bone tissue and periosteum, embryonic stem cells
(ESCs), induced PSCs (iPSCs) and ASCs.
The selection of appropriate cell source for bone tissue engineering depends on several factors
such as:
• Possibility of application of patient’s own (autologous) cells or another person’s (allogeneic)
cells;
• Availability and ease of tissue harvesting with minimal donor site morbidity;
• Efficiency of cell isolation and cell yield;
• Potential of cell proliferation;
• Use of cells that have both osteogenic and vasculogenic potential to support the formation
of vascularized bone;
• Homogeneity of the obtained cell population;
• Control of induction of osteogenic phenotype;
• Phenotype stability and cell safety;
• Automation and good manufacturing practices production.
Among the mentioned candidates, mesenchymal stem cells (MSCs), as a member of the ASC
group, currently possess characteristics that make them the most appropriate cell source for
bone tissue engineering. Unlike ESCs which are pluripotent and have unlimited potential for
proliferation in vitro [5], MSCs possess multilineage differentiation potential and have limited
proliferation capacity [6, 7]. In bone tissue engineering, ESCs gained enormous value as a cell
source for the derivation of multiple lineages present in adult bone, such as osteogenic cells,
vascular cells, osteoclasts, nerve cells and others. Despite increasing interest in the application
of ESCs in bone regeneration strategies, use of this cell source is limited due to political issues
and ethical concerns as well as safety reasons. The primary concern is the source from which
ESCs are derived. The most commonly referenced pluripotent cells are ESCs derived from the
inner cell mass of blastocyst which results in destruction of the embryo [8]. It has also become
clear that pluripotency is a double-edged sword; the same plasticity that permits hESCs to
generate hundreds of different cell types also makes them difficult to control. Transplantation
of hESCs into immune-deficient mice leads to the formation of differentiated tumors compris‐
ing all three germ layers, resembling spontaneous human teratomas [9, 10]. Karyotype
abnormalities have been observed in ESCs as well as in human iPSCs [11]. Therefore, further
studies are needed to ensure the stability and safety of ESC-derived progenitor populations
before their potential use in clinical applications. Because these particular cells have created
an ethical debate, the researchers have investigated fetal stem cells derived from voluntary
interruption of pregnancy as a potential cell source for bone tissue engineering [12]. The cells
that have potential medical applications, especially in organ regeneration [13–17], and
importantly posess no ethical issues concerning their employment are amniotic stem cells.
They are mixture of stem cells that can be obtained from the amniotic fluid [18–20] and the
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amniotic membrane [21]. They represent a novel class of PSCs with intermediate characteristics
between embryonic and ASCs, as they are able to differentiate into lineages representative of
all three germ layers but do not form tumours when injected in vivo [22]. They can develop
into various tissue types including skin, cartilage, cardiac tissue, nerves, muscle and bone [23–
25]. In 2006, Kazutoshi Takahashi and Shinya Yamanaka established for the first time murine
ES-like cell lines from mouse embryonic fibroblasts (MEFs) and skin fibroblasts by simply
expressing four transcription factor genes encoding Oct4, Sox2, Klf4 and c-Myc [26]. They
called these somatic cell-derived cell lines iPSCs. iPSCs exhibit similar morphology and growth
properties as ESCs and express ESC-specific genes. The discovery that somatic cells can be
reprogrammed into iPS cells has already had major effects on research in stem cell biology and
regenerative medicine, but many obstacles remained and need to be resolved to take full
advantage of this technology in research and therapy [27]. Therefore, the current clinical
protocols are based on the use of autologous MSCs as the cell population that is safe and easy
to obtain.
2.2. Sources of human MSCs
Extensive research of adult MSCs started in 1970 when Freidenstein et al. discovered these
cells in bone marrow tissue [28]. Later, the presence of MSC-like population was discovered
in a wide range of adult tissues, including trabecular bone [29], synovium [30], adipose tissues
[31], skeletal muscle [32], periosteum [33], dermis [34], blood [35, 36] deciduous teeth [37],
amniotic fluid [38] and umbilical cord blood [39]. Bone marrow-derived mesenchymal stromal
cells (BM-MSCs) have become one of the main cell sources for bone tissue engineering [40,
41]. Isolation of MSCs from bone marrow requires invasive procedures that can be quite
painful. Bone marrow aspirate could be obtained from the iliac crest, tibia or femur. Typically,
the frequency of MSCs in whole bone marrow of adults is between 5 × 10−4 and 10−5, which
corresponds to yield of a hundred MSCs per milliliter of marrow. Even though BM-MSCs are
rare, they are readily separated from the hematopoietic stem cells in culture by their prefer‐
ential attachment to the plastic surface [42] and can be easily expanded ex vivo. The presence
of MSC in adipose tissue has gained considerable attention because of the ease of accessibility
of adipose tissue and its abundance in the body. Adipose tissue-derived mesenchymal stem
cells (AD-MSCs) were first identified in 2001 by Zuk et al. A major advantage of AD-MSCs is
their relative abundance as well as their faster proliferation rate compared to BM- MSCs, which
allows more rapid expansion to obtain clinically relevant cell numbers [43, 44]. AD-MSCs have
similar osteogenic potential to BM- MSCs with the added advantage of being highly abundant.
For example, as many as 1 × 107 AD-MSCs can routinely be isolated from 300 ml of lipoaspirate,
with purity greater than 95% [45, 46]. Comparative analysis of human BM-MSCs and AD-
MSCs by Li et al. revealed that AD-MSCs have biological advantages in the proliferative
capacity, secreted proteins (basic fibroblast growth factor, interferon-γ and insulin-like growth
factor-1) and immunomodulatory effects, but BM-MSCs have advantages in osteogenic and
chondrogenic differentiation potential and secreted proteins (stem cell-derived factor-1 and
hepatocyte growth factor) [47]. These biological advantages should be considered systemati‐
cally when choosing the MSC source for specific clinical application. Nevertheless, the
utilization of human AD-MSCs in scaffolds for bone tissue engineering has been heralded as
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the alternative strategy of the twenty-first century to replace or restore the function of
traumatized, damaged or lost bone.
MSC-like cells can be derived from the umbilical cord from a newborn baby which contains
two arteries and a vein covered with mucus connective tissue rich in hyaluronic acid, referred
to as a Wharton's jelly [48]. The blood from the umbilical cord is a rich source for pluripotent
cells named as umbilical cord blood derived MSCs (UCB-MSCs). These cells are quite similar
to bone marrow-derived MSCs and have osteogenic potential in an optimized culture [49].
Many investigations have thus far been conducted on bone engineering by using these cells
and various scaffolds [50].
Several stem cell types in dental tissue have been reported including dental pulp stem cells
(DPSCs), stem cells from human exfoliated deciduous teeth (SHED), stem cells of the apical
papilla (SCAP), periodontal ligament stem cells (PDLSCs) and dental follicle progenitor cells
(DFPCs) [37, 51]. Since DPSCs can be easily isolated by enzymatic digestion of pulp tissue,
many studies have been conducted regarding bone engineering with these cells and appro‐
priate 3D scaffolds [52, 53].
2.3. Phenotypic characterization of MSCs
Phenotypic characterization of MSCs is usually carried out using immunocytochemical
detection or fluorescence-activated cell sorting (FACS) analysis of cell surface molecule
expression [54, 55]. Methods of immunodepletion using such techniques as magnet-activated
cell sorting (MACS) have also been used in the negative selection of MSCs [56]. However, the
lack of specific markers renders the characterization of MSCs difficult and sometimes ambig‐
uous, especially because many of these epitopes are shared between hematopoietic and
mesenchymal stem cells. It is interesting that MSCs from different species do not express the
same markers. The use of multiple markers such as cell surface cluster of differentiation (CD)
markers, ECM proteins, cell adhesion molecules, integrins, cytokines genetic and proteomic
fingerprinting can help identify MSCs. The most commonly used markers to identify MSCs
are CD markers. Positive MSC markers include: Stro-1, SH2 (CD105), SH3 (CD73), SH4, CD29,
CD44, CD54, CD90, CD133, CD166 and p75LNGFR, whereas negative markers are CD11,
Cd14, CD19, Cd31, CD34, Cd45, CD79 and HLA-DR [57]. The International Society for Cellular
therapy has provided minimum criteria for defining MSCs. Acceptable MSCs meet the
minimum requirements of CD73, CD90 and CD105 positive and CD14, CD34, CD45 and HLA-
DR negative expression [58].
2.4. Nonimmunogenic properties and immunosuppressive nature of MSCs
Previous studies have shown that yield of MSCs is affected by age and health of a donor. The
trend is that yield is decreased with donor age. Patients with degenerative diseases, such as
osteoporosis and osteoarthritis, tend to have lower MSC yield although they would benefit
the most from MSC-based therapies. The alternative is the use of allogeneic MSCs because they
have low immunogenic potential and immunosuppressive properties. Immunologic pheno‐
types of hMSCs are: positive expression for major histocompatibility complex (MHC) class I
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molecules, minimal expression for MHC class II and do not express the co-stimulatory
molecules CD40, CD40 ligand, CD80 and CD86 [59–62]. MSCs do not fully activate T cells
owing to the absence of CD80 and CD86 in their membrane. Apart from not being recognized
as alloantigens, MSCs are able to suppress the activation and proliferation of different cells of
the host immune system [59, 63–66]. Interleukin-10, transforming growth factor beta (TGF-β),
hematopoietic growth factor (HGF), prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase
(IDO) and nitric oxide (NO) were some of the soluble molecules associated with the immu‐
nosuppressive effect of MSCs [67–69]. Another important soluble molecule involved in the
immunoregulation of MSCs is HLA-G5, a non-classical human leukocyte antigen (HLA) class
I protein that protects the fetus against rejection from the maternal immune system [70]. The
HLA-G5 isoform released by MSCs can suppress allogeneic T cell proliferation and can also
induce the expansion of CD4+CD25highFOXP3+ regulatory T cells (Tregs). With regard to innate
immunity, HLA-G5 is able to inhibit the lysis of MSCs mediated by NK cells, as well as the
secretion of IFN-γ by these cells [71].
2.5. Tumor formation risk in MSCs application
In general, it is believed that MSCs can be safely cultured in vitro without risk of spontaneous
malignant transformation [72], but there have been no reports of human trials demonstrating
the formation of tumors with culture-expanded MSCs [73]. Concerns have been raised about
the safety of MSCs for clinical use as there have been some reports of sarcoma formation by
cultured murine MSCs in vitro and in vivo [74, 75]. The mechanism by which MSCs are
transformed into malignant cells is known to be related to chromosomal abnormalities,
including structural and numeric aberrations, and increases with higher passage numbers.
Rubio et al. showed that although MSCs can be managed safely during the standard ex vivo
expansion period (6–8 weeks), human MSCs can undergo spontaneous transformation
following long-term in vitro culture (4–5 months), and the transformed cells lead to the
formation of tumors in mice [76].
2.6. Osteogenic differentiation of MSCs
Various in vitro protocols have been developed to induce hMSCs to differentiate into meso‐
dermal lineages, such as osteoblasts, chondrocytes, adipocytes, as well as transdifferentiate
into tissue cells derived from different germ layers, such as neuronal cells or insulin-producing
cells [55, 77, 78]. Osteogenic differentiation is a highly programmed process consisting of many
stages, including proliferation, differentiation, matrix deposition, mineralization and matrix
maturation. The general protocol for in vitro bone differentiation of MSCs involves incubation
of the cell monolayer in a culture medium containing DEX, β-glycerophosphate and ascorbic
acid for a period of 2–3 weeks (Figure 1) [79]. DEX is a synthetic glucocorticoid that stimulates
MSC proliferation and is essential for osteogenic differentiation [80, 81]. Although the
mechanisms underlying DEX's effects are not well known, it has been speculated that DEX
upregulates the beta catenin-like molecule TAZ, which results in upregulation of Runx2-
related transcription factor and osteogenic differentiation [82]. The optimal concentration of
this reagent for MSC bone differentiation is approximately 10 nM, which corresponds to
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physiologic concentrations [83]. Organic phosphate released after enzymatic hydrolysis of beta
glycerol phosphate plays an important role in matrix mineralization. This free phosphate is
usually applied in 5–10 mM concentrations for MSC bone differentiation. Ascorbic acid is a
cofactor in the hydroxylation of prolines and lysine moiety of collagen molecules and is an
abundant protein in the ECM. This reagent is used in 50–500 μM concentrations [84]. When
MSCs are cultured in osteogenic media, they express the same markers as bone-forming
osteoblasts that are responsible for laying down the matrix and mineral during new bone
formation in vivo. The osteogenic differentiation of MSCs in vitro has been divided into three
stages. The first stage (days 1–4) is the proliferation stage where a peak in the number of cells
is seen. This is followed by early cell differentiation (from days 5 to 14), which is characterized
by the transcription and protein expression of alkaline phosphatase (ALP). After this initial
peak of ALP, its level starts to decline. Also found at an early stage is the expression of a
collagen type I matrix onto which the mineral is deposited. The final stage (from days 14 to
28) results in a high expression of osteocalcin and osteopontin, followed by calcium and
phosphate deposition [4, 85].
Figure 1. Monolayer of mesenchymal stem cells derived from human bone marrow before (A) and after 3 weeks of (B)
differentiation. Arrows mark bone-forming nodules.
In addition to osteogenic supplements, there are other substances that act as biochemical
signals capable of triggering cellular processes like growth, proliferation or differentiation.
The most common growth factors in bone tissue engineering are listed below.
Bone morphogenetic proteins (BMPs) are a family of cytokines that stimulates the proliferation
of chondrocytes and osteoblasts and increases extracellular matrix production. BMPs induce
the differentiation of MSCs into osteoblasts. BMPs allow not only skeletal tissue formation
during embryogenesis, growth, and adulthood but also bone healing process. In newborns’
skeletons, BMPs can be found in the collagen fibers of the bone matrix and also in cells located
in the periosteum and the bone marrow. After a fracture, BMPs’ growth factors diffuse from
bone matrix and activate osteoprogenitor cells which, in turn, produce more BMPs [86].
Fibroblast growth factors (FGFs) stimulate the proliferation of mesenchymal cells, osteoblasts
and chondrocytes. FGFs enhance the growth of different tissues due to their angiogenic
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properties. FGF-2 or bFGF is the most studied cytokine of this family for bone regeneration
applications [87].
Insulin-like growth factors (IGFs) promote the proliferation of osteoblasts and chondrocytes and
induce matrix secretion from both cell types [87]. IGFs stimulate collagen synthesis and
mineralization of bone tissue [88].
Platelet-rich plasma (PRP) is another known source of various growth factors, namely, platelet-
derived growth factor, transforming growth factor-β and vascular endothelial growth factor.
The applicability of PRP for the repair of bony defects is well established [89] and several
investigators have advocated the use of this product in combination with MSCs [90].
3. Scaffolds in bone engineering
3.1. Scaffold properties
The evolution of bone implant devices has resulted in an increase in knowledge about the
microenvironment where the replacement will occur, which results in changes in requirements
and properties of the biomaterials used. This evolution can be measured by defining three
different generations. However, these generations are not chronological but technological
since there is currently active research and development for each. First-generation bone graft
substitutes require the biomaterial to match the physical properties of the tissue to be replaced,
while maintaining inertness with the tissue microenvironment. These include metals such as
stainless steel, titanium and alloys; ceramics such as alumina and zirconia; and polymers such
as silicone rubber, polypropylene and polymethylmethacrylate. Second-generation bone graft
substitutes are made biodegradable with the aim that the rate of degradation matches the
healing rate of the injured bone tissue. These biomaterials are based on the use of synthetic or
natural polymers that can provide a controlled chemical breakdown under physiological
conditions into inert products that can be resorbed by the body. Examples of the synthetic
polymers include polylactide, poly(ε-caprolactone) and polyglycolide; and collagen, chitosan
and hyaluronic acid for natural ones. The mechanical and osteoconductive properties of these
polymers can be improved by forming composites with bioactive ceramics. Third-generation
bone graft substitutes try to get closer to the autograft standard by using biomaterials capable
of inducing specific cellular responses at the molecular level, by integrating the bioactivity and
biodegradability of second-generation devices. This type of bone graft is based on the concept
of bone tissue engineering, which focused on creating a device that enhances bone repair and
regeneration by incorporating bone progenitor cells or/and bioactive signals (e.g., growth
factors, small molecules) to stimulate cells into a scaffold made of various natural or synthetic
biomaterials or their combination and with sufficient vascularization to allow access to
nutrients to support this process. Nowadays, many groups worldwide seek to develop
scaffolds with osteoinductive properties that would enhance bone healing. These scaffolds
have to accomplish certain requirements and have to be:
Biocompatible—cells must populate the scaffold, adhere and proliferate. They should be able
to migrate as well as differentiate. Overall, cell function should not be compromised. The
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scaffolds should enable unobstructed transport of nutrients, gases, signaling molecules,
proteins and waste products in, out and within the scaffold.
Biodegradable—the scaffold should be replaced with host/donor cells (tissues). Therefore,
scaffolds must be biodegradable and byproducts must not be toxic. Ideal scaffold degradation
should mirror the rate of new tissue formation.
Biofunctional—the scaffold should meet as many as possible functional requirements of the
replaced tissue. Good scaffold should have specific mechanical properties and architecture,
similar to properties of the replaced bone tissue. Properties like elasticity, permeability,
compressibility, viscoelastic behavior, tensile strength and failure strain [91] should be similar
and should give shape to the tissue that is regenerated on it [92]. It is very important to have
strong, but at the same time, porous bone grafts. The pores should be big enough to allow
smooth cell migration and proliferation besides vascularization and small enough to enable
cell-to-cell communication and critical cell repopulation of the pores. Pores are crucial in a
process of degradation. Their size should allow and promote scaffold degradation.
The main disadvantage of scaffolds is the lack of vascularization. Inspired by the nature of
bone, different scaffolds have been studied extensively, and the main challenge is to precisely
balance a desired structural strength and porosity. To design bone scaffolds, materials should
have the desired biological properties for a specific application and should not be immuno‐
genic causing inflammatory response. The long-term goal is the development of the scaffold
that can be applied in a clinical setting. Manufacturing technology should follow good
manufacturing practice (GMP) procedures. Ultimately, the main goal is to develop scaffold
that fulfills all previously mentioned requirements and has slow-release properties of bioactive
molecule. Multiple factors (signaling peptides, adhesion peptides, growth factors, plasmid
DNA, antibodies, microRNAs, etc.) can be incorporated into scaffolds to promote osteoblast
migration, to manipulate tissue formation and to effectively enhance bone regeneration [93].
For instance, bone morphogenic protein 2 (BMP-2) was photo-crosslinked into biodegradable
diblock copolymers PEG-PLA and was slowly released as the polymer degrades [94]. Another
approach is to covalently bind the adhesion peptide like well-known arginine-glycine-
aspartate ligand or chemotactic factor like platelet-derived growth factors (PDGFs), to attract
osteoblast and promote osteogenesis [95, 96] or incorporate angiogenic (FGFs [97]) and anti-
angiogenic factors to control scaffold vascularization [98]. MicroRNAs can post-transcription‐
ally regulate gene expression and alter bone regeneration [99]. There are many problems to
that approach, and the major one is controlled release of bioactive substance together with its
rapid dilution. To reduce the risk of BMP dilution following release from the scaffold,
monoclonal anti-BMP antibodies are encapsulated within the scaffold [100].
3.2. Scaffold types
With respect to source of biomaterials, scaffolds can be divided into two main groups: the ones
made from natural and the ones made from synthetic materials. The natural biomaterials are
obtained from natural sources and processed to make desired scaffolds. A few decades ago,
researchers have discovered that decalcified bone matrix (DBM) possesses inherent osteoin‐
ductive properties (http://www.ncbi.nlm.nih.gov/pubmed/4870495), and DBM was used in
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the treatment of clinical orthopedic situations which has shown favorable results [101, 102].
Decellularized ECM (mammalian extracellular matrix) scaffolds recovered from allografts
(tissue from individuals of same species) and xenografts (tissue from individuals of different
species) have a desired three-dimensional porous structure and can be repopulated by host
bone-forming cells. ECM is a complex of different glycosaminoglycans, glycoproteins and
huge number of different small proteins. The cells can easily attach, grow and differentiate
with excellent viability. Decellularization and treatments such as freeze-drying, irradiation
and washing with acid minimize their immunogenicity, but some epitopes can still be
recognized by the host. These treatments prevent any infection to be transferred from the
tissue, but can affect their mechanical and biological properties [97]. Most commonly used
biological materials for bone tissue engineering are chitosan, collagen, hyaluronic acid,
alginate, elastin, cellulose, fibrin, gelatin, etc. Chitosan is a hydrophilic, linear polysaccharide
(suh, matthew, application of chitosan-based) obtained by alkaline deacetylation of chitin from
shrimp and other crustacean shells. It has many beneficial properties, such as biocompatibility
(no inflammatory or allergic reaction, (chatelet, damour, influence of the degree), biodegrad‐
ability (it is naturally degraded by hydrolytic enzymes such as lysozyme) and no toxicity [103].
Since collagen is the most abundant protein in various tissues including bone, scaffolds made
of collagen are very attractive for biomedical applications. Collagen is composed from two α1
chains and one α2 chain wrapped together by hydrogen and covalent bonds to form right-
handed triple helix. These fibers spontaneously pack together to form long thin fibrils of similar
structure. Collagen is an attractive material for a scaffold synthesis because its mechanical
properties can be altered by crosslinking, either with different chemicals (glutaraldehyde,
formaldehyde, etc.) or with physical treatments (UV irradiation, heating, etc.) [104–106].
Hyaluronic acid is a simple linear polysaccharide composed of a repeating disaccharide, and
it is hydrophilic, nonimmunogenic, and easy to modify and produce. It is easily replaced by
extracellular matrix produced by host cells due to hyalurodinase degradation. These materials
have a huge biological activity; they promote cell adhesion as well as cell growth. They are
biodegradable, allowing host cells to replace the scaffold with their own extracellular matrix.
The main drawbacks are their poor mechanical properties limiting their use as bone grafts and
the reproducibility of their synthesis. Immunogenicity, limited physical and mechanical
stability as well as limited resource of biomaterials have encouraged researches to develop
composites using synthetic materials.
Typically, two individual groups of synthetic biomaterials are used in the fabrication of bone
grafts: ceramics and synthetic polymers. Ceramics polymers (inorganic oxides and salts), such
are hydroxyapatite (HA), β-tricalcium phosphate (β-TCP) and biphasic calcium phosphate
(BCP) are mechanically stiff and have very low elasticity, making them suitable only for bone
tissue grafts. Ceramics perfectly imitate natural bone structure, and cell interaction with
ceramics promotes proliferation as well as differentiation of osteoblasts [107].
Synthetic polymers, such as polystyrene, polyglycolic acid (PGA) and poly-l-lactic acid (PLLA)
acid, have the rewarding and satisfying properties because their architecture can be adjusted
and changed by the composition of the polymer as well as by altering the synthesis method.
However, cell might have difficulties to attach and proliferate on their surface, so there is
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always the risk of rejection due to reduced bioactivity. Degradation of synthetic polymers
becomes the major issue because most of them are degraded by hydrolysis, causing lower local
pH and cell necrosis [108].
Since ceramics have excellent osteoinductive properties but low mechanical strength, and
synthetic polymers exhibit poor osteoinductivity but better mechanical strength and degrad‐
ability, in the past decade researches have been trying to develop the scaffolds made of ceramic
and polymer composites. Most commonly used 3D composites are made of synthetic polymers
such as poly(lactic) acid (PLA), PGA, poly(ε-caprolactone) (PCL), poly(lactic-co-glycolide)
(PLGA), poly(propylene fumarate) (PPF) and natural polymers such as collagen type I and
chitosan. These composites have rigid sponge-like structures often containing HA (133-138
from three-dimensional alexander). Hydroxyapatite increases attachment of mesenchymal
stem cells, differentiation to osteoprogenitors and promotes cell survival [109, 110].
3.3. The ideal scaffold for bone tissue engineering
The ideal scaffold is difficult to obtain and should be biocompatible, bioresorbable, osteocon‐
ductive (must allow bone cells to adhere, proliferate and secrete extracellular matrix), ostein‐
ductive (with the ability to induce new bone formation), osteogenic (should act as MSCs and
osteoblasts reservoir), structurally similar to bone enabling formation of strong bonds with
surrounding bone tissue, as well as it should be easy to use and cost-effective. New approach
includes development of methods to isolate and transplant bone tissue-forming cells, bioactive
matrix materials that act as tissue scaffolds mimicking what happens in nature, and delivery
of bioactive molecules within scaffolds. In the past two decades, many 3D systems have been
Figure 2. Bone graft grown on scaffold made of chitosan and hyaluronic acid. Section of graft stained with hemalaun/
eosin staining shows equal cell distribution, formation of extracellular matrix and scaffold residues.
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studied and some have been commercialized for clinical application. The main advantage of
this system is that cells grown in 3D environment that is more representative to natural bone
tissue. Final goal is to produce a “living” scaffold providing mechanical support, bioactive
signal as well as cells with osteogenic potential. Researchers have developed bioreactors to
mimic physiological conditions. The main advantage is that this system enables controlled
manipulation of all variables. In contrast to classic static in vitro cultures, bioreactors allow to
apply mechanical stimuli that are very important in osteogenic differentiation [111]. Many
different bioreactors to promote good osteogenesis (Koller reactors [112]), spinner flask
bioreactors, [113] have been investigated. Recently developed perfusion bioreactors have
shown high efficiency in uniformed cell seeding on a scaffold, enhanced proliferation, great
supply of oxygen and nutrients throughout the scaffold as well as enhanced osteogenic
differentiation because the pump forces the medium to flow through the scaffold (Figure 2)
[114–117].
4. Systems for 3D cultivation of bone tissue
Ex vivo tissue-engineering (TE) strategies for de novo generation of bone tissue enclose the
combined use of autologous bone-forming cells and three-dimensional scaffold materials
serving as structural support for the cells [118]. Bioreactors are used as a tool for studying and
mimicking in vivo conditions in an in vitro environment for the growth of tissue substitutes
and represent the device used to develop biological processes by closely monitoring and
controlling the environment [119]. Parameters that must be controlled and appropriately






Tissue-engineering bioreactors can be used to aid the in vitro development of new tissue by
providing biochemical and physical regulatory signals to cells, encouraging them to undergo
differentiation and produce extracellular matrix prior to in vivo implantation [120].
This 3D cell expansion on a scaffold poses several challenges. The first challenge is the
transport of nutrients to cells and removal of waste metabolites from the interior of the
scaffold. In 2D cell culture diffusion provides nutrients and oxygen to all cells as well as waste
removal, but in 3D constructs diffusion is insufficient [121]. That represents an important issue
in tissue engineering, limiting the tissue growth due to insufficient nutrient transport [122].
To overcome this problem, scientists developed more complex bioreactor systems 3D tissue
culture to improve the media flow and transport of nutrients to cells which contribute to
balanced development of tissue [118]. Dynamic bioreactor culture systems are essential for in
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vitro cultivation and maturation of tissue-engineering bone grafts, in particular for larger bone
grafts where the core of the scaffold is more than 200 μm from the surface. Bioreactors improve
the mass transport of nutrients and overcome the diffusion limitation of traditional static
culture [123]. Bioreactors bring several advantages into the culture of functional tissues. They
do not only increase mass transport inside three-dimensional structures but also reduce the
handling steps, hence reducing contamination potential.
Fluid shear stress caused by mixing or perfusion the medium is also very important for bone
tissue engineering because it exposes the cells to mechanical stimulation. In vivo, mechanical
loading increase production of prostaglandins, alkaline phosphatase, collagen type I, along
with osteoblast proliferation and mineralization [124]. Mechanical loading of the skeleton
causes interstitial fluid flow through lacunar and canalicular space of bones. The cells lining
these spaces are then influenced by the mechanical stimulation provided by the fluid flow,
differentiating or proliferating accordingly [125, 126]. Based on this knowledge, it is clear that
the recapitulation of these mechanisms in vitro is essential for the growth and the regenerative
properties of human osteoprogenitor cells seeded onto scaffolds [127]. In vitro, mechanical
stimulation can encourage cells to produce extracellular matrix (ECM) in a shorter time period
and in a more homogeneous manner than in static culture [128]. A benefit of ECM production
is the increase in mechanical steadiness of the scaffold and tissue graft. Another important
advantage of bioreactors is induced cellular differentiation. Mechanical stimuli can be used
to encourage stem cells down a particular path and hence provide the cell phenotype required
[129].
As well as providing mechanical stimulation, bioreactors can also be used to improve cellular
spatial distribution. A heterogeneous cell distribution is a major problem in developing three-
dimensional tissue or organ in vitro [130]. Scaffolds in larger size range are easily fabricated,
but problems arise with culturing cells on these scaffolds. As the size of the scaffold increases,
diffusion of cells to the center becomes more difficult. Static culture conditions result in
scaffolds with few cells in the center [131]. Thus, bioreactors can be used in tissue-engineering
applications to overcome problems associated with traditional static culture conditions,
improve cellular distribution and accelerate construct maturation [132] while applying
biophysical signals to constructs to improve tissue formation in vitro prior to in vivo implan‐
tation [120].
The ultimate design of a tissue engineering bioreactor system must: (i) ensure a controlled and
rapid cell growth; (ii) facilitate uniform cell distribution; (iii) provide and maintain the
physiological requirements of the cell (nutrients, oxygen, growth factors); (iv) increase mass
transport both by diffusion and convection using mixing medium systems (v) expose cells to
physical stimuli; and (vi) enable reproducibility, control, monitoring and automation. For this
purpose, different dynamic culture systems have been developed. These systems improve
nutrient delivery to the cells and generate shear stress that promotes cell differentiation into
osteoblastic phenotype. Bioreactors for bone engineering applications are broadly classified
into few main categories, including rotating wall vessel, spinner flask, perfusion bioreactor
and compression systems. In addition to these, combinations of different types of bioreactors
have been explored in order to better mimic the bone physiological environment in vitro and
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all these systems for tissue culture are used to achieve a homogeneous cell growth within the
scaffold [120].
4.1. Rotating wall vessel bioreactor
Cells that grow in vitro—outside the body in 2D layers do not behave in the same way as cells
grown in vivo—inside the body. In vivo cells grow three-dimensionally and form tissues that
have modified their structure to perform a specific function and secrete extracellular matrix.
Two-dimensional growth represented a limit to the scientists who wanted to understand
mechanisms that govern cell behavior and tissue formation. In the 1970s, a small NASA group
of scientists began to think about space as a possible answer. The group believed if cells could
be grown without the Earth's gravity influence, they would not settle to the bottom of the
culturing container, instead they would be suspended in the medium and therefore might
compound and form tissue that more closely resembles the tissue in the body [133]. The
rotating-wall vessel (RWV), developed by NASA, was originally designed to protect cell
cultures from high shear forces generated during the launch and landing of the space shuttle.
When the device was tested on the Earth for cells in suspension, cells aggregated and formed
structures similar to tissues. These observations led to the possibility that the bioreactors might
be used to study co-cultures of multiple cell types and their association, proliferation and
differentiation during the early steps of tissue formation [134].
The RWV bioreactor provides a low turbulence culture environment which promotes the
formation of large, three-dimensional cell clusters. Due to their high level of cellular organi‐
zation and specialization, samples constructed in this bioreactor more closely resembled the
original tumor or tissue found in the body. Cartilage, bone marrow, heart muscle, skeletal
muscle, pancreatic islet cells, liver and kidney are just a few of the normal tissues cultured in
rotating bioreactors [133].
The RWV bioreactor (Figure 3A) consists of a cylindrical growth chamber with a gas exchange
membrane. The solid-body rotation is accomplished by a vessel rotating horizontally around
its axis, randomizing the gravitational forces acting on the cell surface. The culture chamber
is completely filled with medium and is oxygenated through a silicone rubber membrane by
an air pump that draws incubator air through the filter. As the vessel rotates, the liquid inside
accelerates until the entire fluid mass is rotating at the same angular rate as the wall. Thus, this
environment eliminates most of the disruptive shear forces associated with a conventional
bioreactor, scaffolds and cells obey simple kinematics and are uniformly suspended in the
culture medium with minimum shear forces. In this environment, cells aggregate and undergo
three-dimensional growth to form tissue-like structures. As aggregates grow during culture,
the speed of vessel rotation is increased to contrary gravitational sedimentation [134].
Cultures using an RWV bioreactor proved useful for growing tissues, such as bone. Many
studies showed enhanced proliferation, distribution and differentiation of osteoprogenitor
cells on scaffolds when cultured in a free fall manner in RWV-based bioreactor systems [135].
Until today, many designs of rotating bioreactor systems have been developed for dynamic
3D bone tissue engineering. One of them is RWV bioreactor with the scaffolds attached to the
external wall by use of stainless steel clamps. External and internal cylinders were driven by
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step motors and compared to the cultivation in static culture. The use of RWV resulted in better
cell proliferation and differentiation. The second one is a rotating bed bioreactor (RBB). In an
RBB, constructs are attached directly on the axis and moved between gas and liquid phases in
an alternating manner. One major benefit of the system besides the positive effect in terms of
proliferation and differentiation is the compatibility with good manufacturing practices (GMP)
standards. Disadvantage of RWV system is the collision of scaffolds with the bioreactor wall,
which may damage scaffolds and disrupt seeded cells. This can be omitted by the use of the
RBB concept. Another major disadvantage of the rotating system is that mineralization is
limited to the outer part of the scaffold. Internal nutrient transport limitations could not be
eliminated by rotation-based bioreactor systems [118]. Rotating wall vessels are limited to the
small-sized constructs due to insufficient transport inside the scaffold. Additionally, because
of the low range of values of shear stress, these systems may not be efficient in promoting
robust osteogenic differentiation. On the other hand, rotating wall vessels allow the accom‐
panying culture of several cell/scaffold constructs. These systems could be adopted to engineer
thin bone substitutes for the reconstruction of flat bones or as bone patches for restorative
applications of the skeletal system [3].
4.2. Spinner flask bioreactor
A simple bioreactor system based on media mixing is the spinner flask (Figure 3B). Spinner
flasks are composed of a glass media reservoir with side arms that can be opened to remove
scaffolds and media and also to allow gas exchange. The flask has a stir bar mechanism that
stirs the media in the flask. They are often used in bone tissue engineering because of the ability
to increase expression of early osteoblastic marker alkaline phosphatase, late osteoblastic
marker osteocalcin and calcium deposition as compared to static culture and rotating wall
Figure 3. Design of rotating vessel (A) and spinner flask (B) bioreactor systems.
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bioreactors. This effect is the result of convective transport of nutrients to the surface of the
scaffold in contrast to the purely diffusional transport in static culture. It also increases the
concentration of oxygen throughout the scaffold [136].
Scaffolds are hanging attached to vertical needles from the top of the vessel and are submerged
in the medium. The top of the vessel is usually used for gas exchange and medium oxygenation.
Mixing of the medium is maintained by stir bar mechanism at the bottom of the vessel. The
convective forces generated during stirring moderate the nutrient concentration gradients at
the surface of the scaffold and produce turbulences that enhance mass transport according to
the center of the samples [3].
Commonly, spinner flasks are around 120 ml in volume (up to 8 liters), are run at 50–80 rpm
and 50% of the medium used in them is replaced every 2 days [137]. An important advantage
of the spinner flask design is its maintenance of well-mixed environment within the flask.
However, spinner flasks are not always an ideal solution, since the constant mixing motion
causes turbulent flow within the capsule and the associated high shear stress. Spinner flasks
have been modified form their original design to reduce the turbulent flow. Current designs
induce small waves during mixing instead of the rough, turbulent flow induced from tradi‐
tional spinner flasks. Spinner flasks are intended for small-scale production and do not appear
to be used as much as other types. They are primarily used for the seeding of cells in 3D
scaffolds until they are ready for more large-scale cell culture procedures [119].
4.3. Perfusion bioreactor
Spinner flasks and rotating wall bioreactors do not effectively perfuse media through the center
of the scaffold. Bioreactors that use a pump system to perfuse media directly through a scaffold
are known as perfusion bioreactors [136]. In perfusion bioreactors, scaffolds are placed in the
perfusion chamber (Figure 4A) in a press-fit manner so that the medium is forced to pass
through the center of the samples [3]. Flow perfusion bioreactors have been shown to provide
more homogeneous cell distribution throughout scaffolds. This has resulted in greater
cellularity throughout the scaffold in comparison to static controls, suggesting the better
nutrient exchange [120].
These bioreactors have an advantage over the others because they provide a uniform mixing
of the media, enabling better control of the environment and the physical stimulation of the
cells in the bone tissue [121]. They are very effective for the culture of mesenchymal stem cells
and have been shown to induce osteogenesis. This is attributed to the ability of the perfusion
system to increase the transport of oxygen and nutrient through the scaffold and expose the
cells to the mechanical stimulation [137]. The optimization of the perfusion bioreactor protocols
for tissue engineering must ensure balance between the transport of substances and waste
metabolites and hold newly synthesized tissue within the scaffold, taking care of the fluid flow
rate which goes through the pores [120]. Many different perfusion bioreactor systems have
been developed, but most systems are based on the similar basic design—media reservoir,
pump, tubing circuit and scaffold chamber. The scaffold is sealed within the chamber so media
cannot flow around it. Thus, media flows directly through the pores of the scaffold [136].
Scaffolds should have interconnected pores and should have between 70 and 99% porosity in
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order to facilitate direct perfusion. In most cases, the major difference between the systems is
the design of the perfusion chamber because it is the key element to ensure deep perfusion of
the scaffold center [121]. Despite these difficulties, many perfusion bioreactor systems have
been developed and tested for bone tissue-engineering purposes [136]. The pump produces a
force that travels through the tubing circuit and perfuse the media through the scaffold pores
in a continuous or noncontiguous way [120]. This force represents the perfusion flow rate
applying mechanical stimulation in the form of shear stress to cells in the scaffold. This
mechanical stimulation proved to be a powerful tool to stimulate osteogenic differentiation,
and data show that cell-matrix and cell-cell junction molecules are capable of converting
mechanical stimuli into biochemical signals.
One of the most important parameters when optimizing a bioreactor is the flow rate. It depends
on the composition, porosity and geometry of the scaffold. The pump is capable of precisely
and consistently pumping flow rates from 0.01 to 6.0 ml/min through each chamber [138]. Still,
there is a big variation of values and there are not many studies that compare a significant
range of flow rates. It appears that the increase in flow rate leads to an increase in the deposition
of mineralized matrix. Very low flow rates such as 0.01 ml/min have been reported to lead to
higher cell viability, but this does not seem an optimal flow rate for bone tissue engineering
as it might be too low to actually accomplish an adequate distribution of nutrients, oxygen and
removal of waste products. It is also necessary to bear in mind that lower values of flow rate
will provide lower values of shear stress, which might facilitate cell attachment and spreading,
Figure 4. Design of the scaffold chambers in perfusion (A) and compression (B) bioreactor systems.
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hence leading to higher values of cell viability. Despite the wide variation of the flow rates
tested, it seems that the optimal values would range from 0.2 to 1 ml/min, depending obviously
on the system being used. This is the range of values that seems to have a more positive effect
on osteoblastic differentiation, ECM deposition and distribution [121]. Perfusion bioreactor is
so far the only system that produces such a force, making it ideal for growing large bone grafts
ex vivo [139].
4.4. Compression bioreactors and combined systems
Compression bioreactors (Figure 4B) were intended to mimic the bone physiological in vitro
environment, characterized by repeated mechanical stimulation required for functional bone
regeneration. Many studies provide evidence that mechanical loading, when combined with
flow perfusion, can play a main role in promoting survival and functional osteogenic differ‐
entiation of the cells within the scaffold. Short-term mechanical stimulation enhanced the
expression of several genes encoding for factors involved in osteogenesis, including RUNX2,
osteopontin, integrin-β1, TGFβR1, SMAD5, annexin-V and PDGFα [3]. These experiments
demonstrate that even short mechanical stimuli can be sufficient to activate the osteogenic
differentiation pathways in human mesenchymal stem cells. Compression bioreactors systems
consist of a motor, a system providing linear motion and a compression chamber in which one
or more clips apply static or dynamic compressive loads directly to the scaffold [3]. The
bioreactor chamber holds the scaffold in place and ensures hermetic sealing as well as force
transmission onto the cell-seeded scaffold. It consists of medium flow distributors, a flexible
force transmitting disk and the intended space for scaffold placement. The power transmission
rack includes a plunger, a pre-load screw and a cam-shaft. The chamber is placed on the clip
and fixed via tightening of the pre-load screw. The camshaft moves the clip in order to apply
a sinusoidal compression pattern onto the bioreactor chamber [140]. The system can be
controlled by a signal generator, and load response can be measured by using linear variable
differential transformers and load cell, respectively. In contrast to static culture, mass transfer
is considerably improved in compression bioreactor culture since compression leads to the
fluid flow through the scaffold [141]. The compression bioreactors provide a promising tool
for bone fracture research and for in vitro estimate of alternative fracture treatments based on
engineered tissue grafts, allowing the reduction of animal experiments.
5. Conclusion
Bone defects that are due to trauma or pathological and physiological bone resorption
represent a global health problem. The need for bone regeneration is one of the central issues
in regenerative medicine. Tissue engineering is becoming a useful addition to medical
therapies for repairing and restoring the function of bone tissue. Bone constructs elaborated
with tissue-engineering principles are a promising substitute for autologous bone graft and
have long been considered the golden standard for repair of large bone defects. Mesenchymal
stem cells from adult tissues are the most suitable cell source for bone tissue engineering.
Although the application of MSCs as cellular material facilitates the construct fabrication, more
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work needs to be done to fully determine the clinical potential, efficacy and safety of stem cell-
based treatments. There is a constant need in the development of new scaffolds that have
optimal characteristics, and are affordable as well as easy for manipulation. Bioreactor
dynamic setting enables better culture conditions and mechanical stimuli for improved bone
tissue growth. In spite of the existing problems, advances in the field are enormous and therapy
using scaffolds, healing signals and stem cells together should be able to solve the current
limitations in managing bone injuries.
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